Lay Summaries and Lay Summary Videos

• PRADAXA ® - Atrial Fibrillation

  Clinical Study Number	1160.204
  Study Indication	Atrial Fibrillation
  Product	PRADAXA ®
  Generic Name	Dabigatran
  Lab Code
  Clinical Phase	IV
  Study Title	Randomised Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral antIcoagulation sTrategy (The RE-CIRCUIT Trial)
  Study Document	Lay summary 1160.204 english

• PRADAXA ® - Atrial Fibrillation

  Clinical Study Number	1160.186
  Study Indication	Atrial Fibrillation
  Product	PRADAXA ®
  Generic Name	Dabigatran
  Lab Code
  Clinical Phase	IIIb
  Study Title	A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110 mg and 150 mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting (RE-DUAL PCI)
  Study Document	Lay summary 1160.186 english

• PRADAXA ® - Venous Thromboembolism

  Clinical Study Number	1160.248
  Study Indication	Venous Thromboembolism
  Product	PRADAXA ®
  Generic Name	Dabigatran
  Lab Code
  Clinical Phase	III
  Study Title	RE-SPECT CVT: a randomised, open-label, exploratory trial with blinded endpoint adjudication (PROBE), comparing efficacy and safety of oral dabigatran etexilate versus oral warfarin in patients with cerebral venous and dural sinus thrombosis over a 24-week period
  Study Document	Lay summary 1160.248 english Lay summary 1160.248 dutch Lay summary 1160.248 french Lay summary 1160.248 german Lay summary 1160.248 italian Lay summary 1160.248 polish Lay summary 1160.248 portuguese Lay summary 1160.248 spanish

• PRADAXA ® - Secondary Prevention , Stroke

  Clinical Study Number	1160.189
  Study Indication	Secondary Prevention ; Stroke
  Product	PRADAXA ®
  Generic Name	Dabigatran
  Lab Code
  Clinical Phase	III
  Study Title	Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral q.d.) in patients with Embolic Stroke of Undetermined Source (RESPECT ESUS)
  Study Document	Lay summary 1160.189 english Lay summary 1160.189 croatian Lay summary 1160.189 czech Lay summary 1160.198 dutch Lay summary 1160.189 estonian Lay summary 1160.189 french Lay summary 1160.189 german Lay summary 1160.189 greek Lay summary 1160.189 hungarian Lay summary 1160.189 italian Lay summary 1160.189 polish Lay summary 1160.189 portuguese Lay summary 1160.189 slovak Lay summary 1160.189 slovene Lay summary 1160.189 spanish Lay summary 1160.189 swedish